NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

Required: CTAG1B expression (≥1+ expression in ≥50% of sampled tumor tissue)

immunohistochemically documented NY-ESO-1 expression, defined as ≥ 1+ expression on either archival or fresh tumor tissue by immunohistochemistry, in ≥50% of the sampled tumor tissue

Required: HLA-A a*0201 or a*0205 positive

HLA-A*0201 and/or HLA-A*0205 positive, as identified by high-resolution genomic deoxyribonucleic acid (DNA) typing of the HLA-A locus

Required: BRAF wild-type

Without proto-oncogene B-Raf (BRAF) mutation

Required: BRAF mutation

With BRAF mutation

Must have received: standard therapy — sarcoma

Patients with sarcoma, who have received at least one line of standard therapy (if available) and failed to respond, progressed or were intolerant to that therapy

Must have received: standard therapy — metastatic melanoma, BRAF wild-type

Without proto-oncogene B-Raf (BRAF) mutation who have received at least one line of standard therapy and failed to respond, progressed or were intolerant to that therapy

Must have received: standard therapy — metastatic melanoma, BRAF mutation

With BRAF mutation who have received at least two lines of standard therapy and failed to respond, progressed or were intolerant to that therapy

Cannot have received: allogeneic stem cell transplantation

Patients with prior allogeneic stem cell transplantation

Cannot have received: organ transplantation

Patients with prior ... organ transplantation